These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1356349)

  • 21. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
    Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
    AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How antibodies block HIV infection: paths to an AIDS vaccine.
    Putney S
    Trends Biochem Sci; 1992 May; 17(5):191-6. PubMed ID: 1350693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunology and the elusive AIDS vaccine.
    Virgin HW; Walker BD
    Nature; 2010 Mar; 464(7286):224-31. PubMed ID: 20220841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.
    Fouts TR; Bagley K; Prado IJ; Bobb KL; Schwartz JA; Xu R; Zagursky RJ; Egan MA; Eldridge JH; LaBranche CC; Montefiori DC; Le Buanec H; Zagury D; Pal R; Pavlakis GN; Felber BK; Franchini G; Gordon S; Vaccari M; Lewis GK; DeVico AL; Gallo RC
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E992-9. PubMed ID: 25681373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing DNA vaccines against immunodeficiency viruses.
    Lu S
    Curr Top Microbiol Immunol; 1998; 226():161-73. PubMed ID: 9479841
    [No Abstract]   [Full Text] [Related]  

  • 29. Impaired T-cell priming and proliferation in cats infected with feline immunodeficiency virus.
    Bishop SA; Williams NA; Gruffydd-Jones TJ; Harbour DA; Stokes CR
    AIDS; 1992 Mar; 6(3):287-93. PubMed ID: 1348945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical issues in mucosal immunity for HIV-1 vaccine development.
    Haynes BF; Shattock RJ
    J Allergy Clin Immunol; 2008 Jul; 122(1):3-9; quiz 10-1. PubMed ID: 18468671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Why can't the immune system control HIV-1? Defining HIV-1-specific CD4+ T cell immunity in order to develop strategies to enhance viral immunity.
    Ostrowski MA; Yu Q; Yue FY; Liu J; Jones B; Gu XX; Loutfy M; Kovacs CM; Halpenny R
    Immunol Res; 2006; 35(1-2):89-102. PubMed ID: 17003512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1/AIDS vaccine development: are we in the darkness.
    Qiu C; Xu JQ
    Chin Med J (Engl); 2008 May; 121(10):939-45. PubMed ID: 18706210
    [No Abstract]   [Full Text] [Related]  

  • 35. [HIV vaccine: how far along are we?].
    Reiss EIMM; van Gils MJ; Sanders RW; de Bree GJ
    Ned Tijdschr Geneeskd; 2020 Sep; 164():. PubMed ID: 33030332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an AIDS vaccine: a daunting epidemiological challenge.
    Nathanson N; Mathieson BJ
    Eur J Epidemiol; 2005; 20(2):123-6. PubMed ID: 15792276
    [No Abstract]   [Full Text] [Related]  

  • 37. AIDS vaccine models: challenging challenge viruses.
    Feinberg MB; Moore JP
    Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
    [No Abstract]   [Full Text] [Related]  

  • 38. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Amara RR; Villinger F; Altman JD; Lydy SL; O'Neil SP; Staprans SI; Montefiori DC; Xu Y; Herndon JG; Wyatt LS; Candido MA; Kozyr NL; Earl PL; Smith JM; Ma HL; Grimm BD; Hulsey ML; Miller J; McClure HM; McNicholl JM; Moss B; Robinson HL
    Science; 2001 Apr; 292(5514):69-74. PubMed ID: 11393868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HIV-1 vaccine race.
    Ho DD; Huang Y
    Cell; 2002 Jul; 110(2):135-8. PubMed ID: 12150921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.